Figure 2.
Randomized controlled trials of switch to a biosimilar compared to continuing with originator infliximab in inflammatory bowel disease patients: proportion with loss of response or worsening disease.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.